Maya Varshney, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 S 5th St, Carrizo Springs, TX 78834 Phone: 830-876-3511 Fax: 830-876-9434 |
Dr. Devendra Varshney, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 S 5th St, Carrizo Springs, TX 78834 Phone: 830-876-3511 Fax: 830-876-9434 |
Michael J Diamond, M D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 704 Hospital Dr, Carrizo Springs, TX 78834 Phone: 830-876-2424 |
Dr. Alfonso Luevano, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 302 S 5th St, Carrizo Springs, TX 78834 Phone: 830-876-9458 Fax: 830-876-2411 |
News Archive
Family Health Network is pleased to announce its participation in a program in partnership with Kerr Health, a subsidiary of the renowned regional pharmacy chain, Kerr Drug. Kerr Health will deploy Family Health Network's Connected for Life(SM) platform to an initial group of patients who require frequent interaction with a pharmacist to assist them with medication therapy management.
Being involved in a healthy, loving relationship is good for the heart, says Vanderbilt Heart and Vascular Institute cardiologist Julie Damp, M.D.
The development of children with Autism Spectrum Disorder (ASD) is much like that of children without ASD at 6 months of age, but differs afterwards. That's the main finding of the largest prospective, longitudinal study to date comparing children with early and later diagnosis of ASD with children without ASD. The study appears in the journal Child Development and has implications for clinical work, public health, and policy.
The iMPak Health Journal for Pain empowers patients to easily record their pain levels before and after their prescribed medication regimen, providing physicians with readily available, useful, patient information.
Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.
› Verified 6 days ago